NASDAQ$UTMD

Utah Medical Products Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Financial performance demonstrated recovery after restrictions on nonessential medical procedures during the COVID-19 pandemic.

Utah Medical Products reported a strong recovery in Q3 2021, with revenues up 20% compared to Q3 2020 and a net income increase of 43.4%. The company exceeded its objective to recover back to its 2019 financial performance.

  • Total consolidated sales were $12,572, up 20% compared to Q3 2020.
  • Domestic U.S. sales increased by 11%, while sales outside the U.S. (OUS) increased by 37%.
  • Net income was $4,206, a 43.4% increase compared to Q3 2020.
  • Earnings per share (EPS) were $1.150, a 43.2% increase compared to Q3 2020.

Headline financials

Total Revenue

$12.6M

Previous: $10.5M+20.0%
EPS (adj)

$1.15

Previous: $0.80+43.7%
Gross Profit Margin

64.2%

No prior period
Operating Income Margin

40.6%

No prior period
Net Income Margin

33.5%

No prior period
Capital Expenditures

-$299K

Previous: -$806K+62.9%
Free Cash Flow

$3.91M

Previous: $2.13M+83.7%
Net Income

$4.21M

Previous: $2.93M+43.4%
Operating Income

$5.1M

Previous: $3.59M+42.1%
Gross Profit

$8.07M

Previous: $6.5M+24.3%
Cash & Equivalents

$64.3M

Previous: $46.3M+38.9%
Total Assets

$120M

Previous: $107M+11.8%
Stock-Based Comp

$41K

Previous: $49K-16.3%

Revenue & EPS history

Utah Medical · Revenue · Quarterly

$12.6M

Q3 2021+20%vs Q3 2020

Revenue by segment

Utah Medical · $7.98M total across 3 segments · Q1 2022

  • Direct Sales
    $3.99M
  • OEM Sales
    $2.72M+42.6%
  • Filshie Device Sales
    $1.28M

Forward guidance

Management expects adjusted consolidated EBITDA of more than $26 million for the full year 2021, and $28 million in 2022.

Tailwinds

  • Adjusted consolidated EBITDA of more than $26 million expected for the full year 2021.
  • Adjusted consolidated EBITDA of $28 million expected in 2022.

Headwinds

  • Risk factors that could cause results to differ materially from those projected include global economic conditions.
  • Market acceptance of products.
  • Regulatory approvals of products.
  • Regulatory and government intervention in healthcare in general.
  • Tax reforms, cybersecurity and foreign currency exchange rates.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.1%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.7%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+6.8%

Q2 2019

Best reaction

-11.7%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.0%-4.3%-7.5%
Q4 2025+1.2%+1.9%+9.5%
Q3 2025-1.1%-1.9%-6.0%
Q1 2025-0.2%+0.9%+4.3%
Q4 2024-1.8%-4.6%-6.9%
Q3 2024-0.3%-0.2%+1.4%
Q2 2024-7.4%-7.2%-8.6%
Q1 2024-1.8%-1.4%-0.2%
Q4 2023-4.3%-7.0%-15.2%
Q3 2023-3.1%+0.0%+4.2%
Q2 2023+0.0%+0.5%-2.8%
Q1 2023+0.8%+0.8%-0.6%
Q4 2022+3.9%+5.5%+4.7%
Q3 2022+3.5%-1.3%-0.1%
Q2 2022+3.6%+6.3%+6.7%
Q1 2022-1.2%-3.1%-4.6%
Q4 2021-3.4%-0.3%-5.9%
Q3 2021+4.7%+1.7%+30.7%
Q2 2021+0.2%+2.9%-0.2%
Q1 2021+0.6%+0.8%-0.4%
Q4 2020+3.5%+5.7%+0.8%
Q3 2020-3.4%-1.7%+6.3%
Q2 2020-5.3%-7.6%-6.7%
Q1 2020-1.8%+4.5%+11.7%
Q4 2019-11.7%-13.9%-16.2%
Q3 2019+1.1%+7.1%+9.2%
Q2 2019+6.8%+9.3%+15.6%
Q1 2019-0.8%-1.5%-5.2%
Q4 2018+3.4%+5.1%-5.2%
Q3 2018+0.7%+1.7%+8.8%
Q2 2018-1.7%+2.1%-5.8%
Q1 2018-2.2%-2.7%-2.7%
Q4 2017-0.2%+0.2%-3.0%
Q3 2017+0.3%+1.1%+6.6%
Q2 2017-0.4%-2.7%-1.1%
Q1 2017+0.4%-0.2%+3.7%
Q4 2016-1.2%+1.0%+1.1%
Q3 2016+0.8%+1.1%+10.4%
Q2 2016-1.3%-2.0%-2.6%
Q1 2016+1.8%
Q4 2015+0.9%
Q3 2015+4.6%
Q2 2015-3.2%
Q1 2015+2.1%
Q4 2014-4.7%
Q3 2014-0.0%
Q2 2014+2.8%
Q1 2014-6.5%
Q4 2013+1.4%
Q3 2013-0.7%
Q2 2013+0.7%
Q1 2013+3.6%
Q4 2012+6.8%
Q4 2011+6.8%
Q3 2012+1.9%
Q2 2012-0.1%
Q1 2011-0.1%
Q1 2012-0.7%
Q4 2009-0.8%
Q3 2010-2.3%
Q3 2011-2.3%
Q4 2010-1.4%
Q2 2011-1.4%
Q2 2010-1.4%
Q1 2010+4.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro